Literature DB >> 21536967

Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis.

P Fusar-Poli1, J M Stone, M R Broome, I Valli, A Mechelli, M A McLean, D J Lythgoe, R L O'Gorman, G J Barker, P K McGuire.   

Abstract

CONTEXT: Alterations in glutamatergic neurotransmission and cerebral cortical dysfunction are thought to be central to the pathophysiology of psychosis, but the relationship between these 2 factors is unclear.
OBJECTIVE: To investigate the relationship between brain glutamate levels and cortical response during executive functioning in people at high risk for psychosis (ie, with an at-risk mental state [ARMS]).
DESIGN: Subjects were studied using functional magnetic resonance imaging while they performed a verbal fluency task, and proton magnetic resonance spectroscopy was used to measure their brain regional glutamate levels.
SETTING: Maudsley Hospital, London, England. PATIENTS AND OTHER PARTICIPANTS: A total of 41 subjects: 24 subjects with an ARMS and 17 healthy volunteers (controls). MAIN OUTCOME MEASURES: Regional brain activation (blood oxygen level-dependent response); levels of glutamate in the anterior cingulate, left thalamus, and left hippocampus; and psychopathology ratings at the time of scanning.
RESULTS: During the verbal fluency task, subjects with an ARMS showed greater activation than did controls in the middle frontal gyrus bilaterally. Thalamic glutamate levels were lower in the ARMS group than in control group. Within the ARMS group, thalamic glutamate levels were negatively associated with activation in the right dorsolateral prefrontal and left orbitofrontal cortex, but positively associated with activation in the right hippocampus and in the temporal cortex bilaterally. There was also a significant group difference in the relationship between cortical activation and thalamic glutamate levels, with the control group showing correlations in the opposite direction to those in the ARMS group in the prefrontal cortex and in the right hippocampus and superior temporal gyrus.
CONCLUSIONS: Altered prefrontal, hippocampal, and temporal function in people with an ARMS is related to a reduction in thalamic glutamate levels, and this relationship is different from that in healthy controls.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536967     DOI: 10.1001/archgenpsychiatry.2011.46

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  48 in total

Review 1.  Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosis.

Authors:  Paolo Fusar-Poli
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

2.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Authors:  Tatsunobu Natsubori; Hideyuki Inoue; Osamu Abe; Yosuke Takano; Norichika Iwashiro; Yuta Aoki; Shinsuke Koike; Noriaki Yahata; Masaki Katsura; Wataru Gonoi; Hiroki Sasaki; Hidemasa Takao; Kiyoto Kasai; Hidenori Yamasue
Journal:  Schizophr Bull       Date:  2013-09-10       Impact factor: 9.306

3.  Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

4.  Neurological soft signs predict abnormal cerebellar-thalamic tract development and negative symptoms in adolescents at high risk for psychosis: a longitudinal perspective.

Authors:  Vijay A Mittal; Derek J Dean; Jessica A Bernard; Joseph M Orr; Andrea Pelletier-Baldelli; Emily E Carol; Tina Gupta; Jessica Turner; Daniel R Leopold; Briana L Robustelli; Zachary B Millman
Journal:  Schizophr Bull       Date:  2013-12-27       Impact factor: 9.306

Review 5.  Attenuated psychosis syndrome in DSM-5.

Authors:  Ming T Tsuang; Jim Van Os; Rajiv Tandon; Deanna M Barch; Juan Bustillo; Wolfgang Gaebel; Raquel E Gur; Stephan Heckers; Dolores Malaspina; Michael J Owen; Susan Schultz; William Carpenter
Journal:  Schizophr Res       Date:  2013-06-14       Impact factor: 4.939

Review 6.  Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis.

Authors:  Hendrik Müller; Sonja Laier; Andreas Bechdolf
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-27       Impact factor: 5.270

Review 7.  Antipsychotic interventions in prodromal psychosis: safety issues.

Authors:  Chen-Chung Liu; Arsime Demjaha
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

Review 8.  Multimodal functional and structural imaging investigations in psychosis research.

Authors:  C Christoph Schultz; Paolo Fusar-Poli; Gerd Wagner; Kathrin Koch; Claudia Schachtzabel; Oliver Gruber; Heinrich Sauer; Ralf G M Schlösser
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-02       Impact factor: 5.270

9.  Sleep dysfunction and thalamic abnormalities in adolescents at ultra high-risk for psychosis.

Authors:  Jessica R Lunsford-Avery; Joseph M Orr; Tina Gupta; Andrea Pelletier-Baldelli; Derek J Dean; Ashley K Smith Watts; Jessica Bernard; Zachary B Millman; Vijay A Mittal
Journal:  Schizophr Res       Date:  2013-10-04       Impact factor: 4.939

Review 10.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.